Cyclin G1 mRNA (CCNG1) (CCNG1)

Cyclin G1 (CCNG1) mRNA is the transcript of the CCNG1 gene, a member of the cyclin family that is uniquely regulated as a transcriptional target of the p53 tumor suppressor protein (UniProt: P51946). Unlike other cyclins that primarily promote cell cycle progression, CCNG1 plays a complex role in the DNA damage response and the G2/M cell cycle checkpoint, often acting as a survival factor in cancer cells (NCBI Gene: 900). Overexpression of CCNG1 mRNA and protein is frequently observed in various malignancies, including osteosarcoma, pancreatic cancer, and breast cancer, where it contributes to uncontrolled cell proliferation and resistance to apoptosis (PubMed: 15150595). As a therapeutic target, CCNG1 is primarily addressed through gene therapy and RNA interference (RNAi) approaches. The most clinically advanced agent, Rexin-G (DeltaRex-G), is a tumor-targeted retroviral vector that delivers a dominant-negative mutant of the CCNG1 gene to compete with endogenous function (PubMed: 16432186). Additionally, experimental siRNA-based strategies have been explored to directly degrade CCNG1 mRNA, thereby inhibiting tumor growth and sensitizing cells to chemotherapy (PubMed: 20633105). This approach leverages the specific overexpression of CCNG1 in cancerous tissues to achieve selective therapeutic effects while minimizing damage to healthy cells.

Other names

CCNGCYCG1Cyclin-G1

Dominant-negative gene expression and RNA interference-mediated degradation of endogenous transcripts